Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national
3
×
national blog main
national top stories
new york top stories
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
europe top stories
fda
indiana blog main
indiana top stories
new york blog main
novartis
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
What
drug
3
×
patients
3
×
fda
market
medicine
new
advantages
approved
atrophy
bar
bio
brings
cancer
daily
eisai
evrysdi
expect
flags
friday
gamble
green
higher
home
incidence
intended
lights
liquid
lorcaserin
loss
marketing
medco’s
mover
muscular
oral
payers
physicians
plan
post
pricing
pulls
Language
unset
3
×
Current search:
drug
×
unset
×
national
×
patients
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone